RxDoctor Payments DataLook up a doctor →

Thomas Arnold, MD

Neurology · Cordova, TNNPI 1366494668

Payments from drug & device makers

$5,480,821in general payments, 2019–2025

Across 1,556 payments — averaging $3522.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.7M
  • Genentech, Inc.$1.2M
  • F. Hoffmann-la Roche AG$528K
  • E.r. Squibb & Sons, L.L.C.$22K
  • UCB SA$18K
  • Bristol Myers Squibb$10K
  • plus $20K from 54 others
$26,167in research payments, 2019–2025

Across 5 payments — averaging $5233.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$26K

What the payments were for

  • Speaking & faculty fees$1931%
  • Food & beverage$18,93197%
  • Education$4412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly13$3,676,684
Genentech, Inc.63$1,205,630
F. Hoffmann-la Roche AG94$527,785
E.r. Squibb & Sons, L.L.C.5$22,170
UCB SA4$18,251
Bristol Myers Squibb38$10,340
AbbVie(2 entities)297$2,351
Novartis115$1,716
Teva Pharmaceuticals USA, Inc.112$1,648
Takeda Pharmaceuticals U.S.A., Inc.1$1,000
Amgen(2 entities)53$970
EMD Serono, Inc.87$884
UCB, Inc.35$788
Genentech USA, Inc.47$682
Neurocrine Biosciences, Inc.30$581
AstraZeneca(2 entities)35$578
Amneal Pharmaceuticals LLC45$552
Pfizer49$488
Biogen29$486
Lilly USA, LLC32$461
Argenx US, Inc.20$409
TG Therapeutics, Inc.16$406
MDD US Operations, LLC21$363
Lundbeck LLC20$342
Acorda Therapeutics, Inc17$312
SK Life Science, Inc.15$260
ANI Pharmaceuticals, Inc.6$260
Alnylam Pharmaceuticals Inc.13$252
Otsuka America Pharmaceutical, Inc.15$214
Avanir Pharmaceuticals, Inc.13$206
Akcea Therapeutics, Inc.10$201
CSL Behring13$198
Acadia Pharmaceuticals Inc13$193
Adamas Pharmaceuticals, Inc.10$186
Sunovion Pharmaceuticals Inc.12$171
Upsher-smith Laboratories LLC11$171
Sanofi9$171
Abbott5$170
Eisai Inc.11$165
Harmony Biosciences LLC8$165
Tanabe Pharma America, Inc.11$161
Biohaven Pharmaceuticals, Inc.13$155
Johnson & Johnson(2 entities)9$142
Biohaven Pharmaceutical Holding Company Ltd.9$142
Neurelis, Inc.8$142
Boston Scientific6$120
Intuitive Surgical1$113
Banner Life Sciences, LLC6$93
Supernus Pharmaceuticals, Inc.5$75
Vanda Pharmaceuticals Inc.5$75
Kyowa Kirin, Inc.5$75
Insightec,inc1$67
Mallinckrodt Enterprises LLC4$57
Mallinckrodt Hospital Products Inc.3$55
Jazz Pharmaceuticals Inc.3$54
Axsome Therapeutics, Inc.2$53
Merz Pharmaceuticals, LLC2$51
Catalyst Pharmaceuticals, Inc.3$45
Scilex Pharmaceuticals Inc.2$39
Assertio Therapeutics, Inc.3$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,480,821 in reported general payments places this provider in the 95th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$180,076
Medicare patients
398
Services billed
5,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate27$152,560
GammakedImmune Globul G/Gly/Iga Avg 4611$142,717
AustedoDeutetrabenazine17$85,227
Nurtec OdtRimegepant Sulfate36$63,285
RytaryCarbidopa/Levodopa26$45,936
Aimovig AutoinjectorErenumab-Aooe39$29,045
OxycontinOxycodone Hcl26$20,197
Lamotrigine OdtLamotrigine13$14,244
UbrelvyUbrogepant16$14,093
Gabapentin397$10,210
Memantine Hcl209$7,050
Carbamazepine ErCarbamazepine31$6,993
Rivastigmine16$3,712
Lacosamide46$3,700
Lamotrigine95$2,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone, Austedo$1,648$237,78744 claims
PfizerNurtec Odt$488$63,28536 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$552$47,13938 claims
AbbVieUbrelvy$2,351$14,09316 claims
Upsher-smith Laboratories LLCTopiramate$171$1,58180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 361 neurology providers in Tennessee.

Other neurology in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →